Automated Specialty Instrumentation, Management, and Education

Automated microbiology uses several distinct instrument families. A processor can inoculate and streak plates, apply labels, move media, and capture images. An incubator can control atmosphere and temperature while imaging growth at defined intervals. A continuous-monitoring blood-culture instrument detects a change associated with microbial metabolism. Identification and antimicrobial-susceptibility systems read biochemical, growth, proteomic, or molecular responses from a prepared isolate or specimen.

The table lists each automated stage and the laboratory control it requires.

A positive blood-culture signal means the bottle crossed the instrument's detection rule. It does not identify the organism or prove clinical significance. Follow your laboratory's positive-bottle procedure. It commonly includes a Gram stain, subculture or validated direct testing, identification, susceptibility testing when indicated, and urgent communication.

MALDI-TOF identification compares a prepared isolate's mass spectrum with a validated reference library. Identification quality depends on the input colony, extraction, target plate, matrix, calibration, spectrum, library content, and acceptance threshold. A high score is not valid for a mixed culture or for an organism absent from the library, because the software can only compare the acquired spectrum with the spectra in its library. The general mass-spectrometry principle is covered in Quantitative Instrument Measurement Principles.

Automated antimicrobial-susceptibility systems produce measurements that software interprets with the configured organism, drug, method, and breakpoint set. The laboratory adopts a current corrected standard, verifies the system, controls expected performance, and manages results outside the platform's validated capability. Current United States CLSI interpretive criteria are in M100, 36th edition, dated January 2026. CLSI posted a correction notice for this edition in July 2026, and the laboratory applies the corrected tables before use.^{1,21 Carroll KC, et al. Manual of Clinical Microbiology. 2023.2 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 2026.} The microbiology lessons describe organism-specific identification, resistance, and reporting algorithms.

Automated blood-cell analyzers combine several measurement channels. The method assigned to one reported parameter may differ between platforms.

An analyzer classifies events from the combined signals and reports counts, indices, distributions, and flags. The analyzer raises a flag when its rules detect a finding that needs review. Resolve each flag before release. A flag does not explain the result. It may reflect an unexpected population, poor separation, a result outside an instrument limit, a specimen problem, or a known interference pattern.

Impedance cannot distinguish cells from other particles of similar pulse size. Platelet clumps, red-cell fragments, very small red cells, large platelets, nucleated red cells, and damaged leukocytes can cross channel boundaries. Cold agglutination can lower the measured red-cell count and raise the mean cell volume (MCV) and the calculated mean cell hemoglobin concentration (MCHC), because clumped red cells pass the aperture together and count as one large event. Lipemia, icterus, a very high leukocyte count, or another source of turbidity can bias a photometric hemoglobin result. The actual pattern and correction depend on the analyzer.^{3,43 Gulati G, et al. Unreliable automated complete blood count results. 2022.4 Keohane EM, et al. Rodak's Hematology. 2025.}

Your laboratory's procedure maps each flag or implausible pattern to an action. Options include inspecting the specimen, mixing and rerunning, warming under a validated cold-agglutinin procedure, dilution, an alternate channel or method, a manual count, a blood-film review, or referral. Rerunning the specimen without correcting the cause does not resolve the flag.

Liquid controls, calibration, calibration verification, background checks, carryover checks, retained-patient monitoring, moving averages (running averages of sequential patient results), delta checks (comparison of a result with the same patient's previous result), and film-review rules serve different purposes. Moving averages and delta checks depend on patient mix and validated limits. They supplement controls and cannot replace required control procedures. CLSI H26, second edition, covers validation, verification, calibration, and quality assurance of automated hematology analyzers. The second edition dates from 2010, was reaffirmed in September 2016 with no content revision, and remains the current edition.^{55 Clinical and Laboratory Standards Institute. Validation, Verification, and Quality Assurance of Automated… 2010.}

For applicable nonwaived test systems, 42 CFR §493.1255 requires calibration verification following the manufacturer's instructions with at least a minimal or zero value, a midpoint value, and a maximum value near the upper limit of the reportable range, at least once every 6 months and whenever any of the following occur:^{66 Electronic Code of Federal Regulations. 42 CFR part 493. 2026.}

• a complete change of reagents for a procedure is introduced, unless the laboratory demonstrates that changing reagent lot numbers does not affect the range used to report patient results and control values are not adversely affected;
• major preventive maintenance or replacement of critical parts that may influence test performance;
• control materials reflect an unusual trend or shift, or are outside acceptable limits, and other means of assessing and correcting unacceptable control values fail to identify and correct the problem;
• the laboratory's established schedule for verifying the reportable range requires more frequent verification.

Calibration is a separate requirement. Perform and document it per the manufacturer's instructions with the recommended frequency, and repeat it whenever calibration verification fails the laboratory's acceptable limits. Manufacturer requirements can be more stringent.

A hemostasis analyzer detects a clot, enzyme reaction, antigen, platelet response, or whole-blood viscoelastic change. Each principle has its own endpoint and its own interferences, so results from different principles cannot be interchanged.

A random-access coagulometer can identify primary tubes, aspirate citrated plasma, add reagents, time reactions, apply calibration, display reaction curves, repeat or dilute according to rules, and transmit results. Barcode and cap-piercing features reduce selected handling errors. These features do not detect every clot, fill error, wrong anticoagulant, drug effect, or optical interference, so specimen inspection and curve review remain part of every run. CLSI H47, third edition, provides current guidance for the one-stage prothrombin time (PT) and activated partial thromboplastin time (APTT) in citrated platelet-poor plasma.^{77 Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial… 2023.}

Interference in chromogenic anti-Xa assays

A chromogenic heparin anti-Xa method measures factor Xa inhibition after the assay's reaction steps. Residual apixaban, rivaroxaban, edoxaban, or another direct factor Xa inhibitor adds to that inhibition. A heparin-calibrated anti-Xa result may therefore appear falsely high as a heparin result during a transition from an oral factor Xa inhibitor, and the assay cannot separate the drugs without a validated approach. Clot-based PT and APTT have their own drug- and reagent-dependent sensitivity and do not avoid this interference. Follow your laboratory's transition and monitoring protocol, which accounts for the medication, dose timing, renal function, assay, and available alternatives.^{88 Bazydlo LAL, et al. ADLM guidance document on coagulation testing in patients using… 2025.}

A chromogenic method avoids some clot-detection problems and remains subject to molecular interference, sometimes to a clinically important degree.

Point-of-care and viscoelastic systems

Point-of-care coagulation instruments miniaturize mechanical, optical, or electrochemical detection in a cartridge or strip. Activated clotting time supports selected high-dose heparin workflows. PT and international normalized ratio (INR) devices support selected vitamin K antagonist monitoring workflows. Whole blood, capillary collection, cartridge chemistry, and calibration differ from the central laboratory's citrated-plasma method. Each device therefore needs validation, operator controls, comparison with the laboratory method, and a procedure for error, out-of-range, unexpected, or discordant results. FDA recommends laboratory confirmation when a point-of-care INR exceeds 4.5 because disagreement increases at higher values. Device instructions and the laboratory procedure may add other confirmation criteria.^{99 US Food and Drug Administration. Information for health care providers using INR test meters in a…} The point-of-care testing (POCT) comparability section connects these checks to oversight of the testing program.

Viscoelastic testing follows whole-blood clot initiation, propagation, maximum strength, and lysis. Thromboelastography (TEG) commonly uses an oscillating cup with a suspended pin. Rotational thromboelastometry (ROTEM) commonly uses a rotating pin in a stationary cup. The systems use different assays and parameter names:

Interpret each parameter with the device, activator, cartridge, time point, reference interval, and clinical algorithm used. Early trace information may appear before the full test completes. Train staff to assess curve quality and limitations along with the numeric result, because the instrument reports a number from a poor-quality trace in the same format as any other result.

Platelet-function and molecular methods

Light-transmission aggregometry follows increasing light transmission as platelets aggregate in platelet-rich plasma after agonist addition. Whole-blood impedance aggregometry follows platelet adhesion and aggregation at electrodes. Closure-time systems draw blood through a coated aperture under defined flow. Cartridge assays may use agonist-specific optical signals. Platelet count, hematocrit, collection, processing time, medications, agonist, and inherited or acquired conditions affect these methods. A closure time neither establishes nor excludes von Willebrand disease or a platelet disorder.

Molecular hemostasis testing uses the extraction, amplification, and sequencing principles in Flow Cytometry, Immunoassay Automation, and Molecular Methods. Clinical utility determines whether a technically detectable variant belongs in a panel. Hemostasis Disease States and Laboratory Determinations covers factor V Leiden, prothrombin G20210A, hemophilia, von Willebrand disease, platelet testing, and other disease-specific interpretation.

Instrument selection starts with the service the laboratory must provide:

• test menu, specimen types, volume, peak arrival pattern, and required turnaround;
• measurement principles, interferences, measuring intervals, and result quality;
• hands-on time, throughput under the actual mix, reagent capacity, maintenance, and downtime;
• footprint, utilities, water, ventilation, waste, noise, ergonomics, and safety;
• open or closed consumables, lot management, storage, expiration, and supply resilience;
• interface capability, cybersecurity, data retention, middleware, autoverification (automatic release of results that pass the configured rules), and audit trail;
• service response, remote support, staff expertise, backup method, and referral plan;
• acquisition, reagent, control, calibration, labor, service, repeat, waste, and downtime costs.

Vendor throughput under ideal loading may not predict local performance. Model the actual mix of routine, urgent, repeat, reflex, maintenance, and quality-control work. Verify the installed system before patient reporting, including performance characteristics, specimen routing, rules, flags, calculations, units, reference intervals or decision limits, critical results, interface transmission, and downtime recovery.

Cost and turnaround

A basic unit-cost estimate is:

Cost per reportable result = costs assigned to the test for a defined period ÷ reportable patient results produced in that period

Define both numerator and denominator before comparing instruments. The numerator may include reagents, consumables, controls, calibration, proficiency testing, repeats, labor, service, depreciation or lease, middleware, utilities, waste, and allocated overhead. The denominator should follow the stated accounting rule and usually excludes controls, calibrators, failed tests, and repeats that do not create another reportable patient result. The largest cost category differs among laboratories.

Measure turnaround time in separate intervals to locate delays:

• order or collection to laboratory receipt;
• receipt to preparation or analyzer loading;
• loading to analytic completion;
• completion to review and release;
• release to required notification or clinical receipt.

A shorter analytic time does not correct a long collection, transport, queue, review, or notification delay. Map the workflow first. Record each handoff, decision, wait, repeat, and failure route before changing staffing or equipment.

US CLIA roles depend on test complexity. A laboratory director is required in every nonwaived laboratory. Moderate-complexity testing requires a technical consultant. High-complexity testing requires a technical supervisor and one or more general supervisors. Moderate- and high-complexity laboratories also require a clinical consultant and a sufficient number of qualified testing personnel. One qualified individual may hold more than one role when the regulations permit it.^{66 Electronic Code of Federal Regulations. 42 CFR part 493. 2026.}

A written delegation names the duty, qualified designee, authority, limits, and documentation. The laboratory director remains responsible for ensuring that delegated functions are properly performed. A job title alone cannot confer a CLIA duty for which the person lacks the required qualifications. CMS states specifically that personnel who do not meet the regulatory qualifications of a technical consultant, technical supervisor, or general supervisor cannot perform or be designated to perform competency assessments.^{1010 Centers for Medicare & Medicaid Services. Assessing Personnel Competency. 2025.}

Staffing should reflect test complexity, workload, peak timing, turnaround needs, maintenance, quality work, leave coverage, and the backup plan. 42 CFR §493.1487 requires a sufficient number of qualified individuals for the volume and complexity of testing performed. A staffing model based only on average daily volume can fail during shifts with concentrated arrivals or limited supervision.

2026 CLIA proposal. On October 8, 2026, the Centers for Medicare & Medicaid Services (CMS) and Centers for Disease Control and Prevention (CDC) proposed revisions to personnel qualifications, including the degree definitions used to assess eligibility. They also proposed allowing qualified laboratory personnel to review digital laboratory data, results, and images remotely under the primary testing laboratory's CLIA certificate. Cytology is excluded from that virtual-access proposal. A separate proposed change would allow digital images in gynecologic cytology proficiency testing. These provisions are proposals. Current CLIA requirements and laboratory procedures govern practice. Public comments are due December 7, 2026.^{1212 Centers for Medicare & Medicaid Services… Clinical Laboratory Improvement Amendments of 1988 (CLIA)… 2026.}

Adult learners bring prior experience and engage best when training addresses a recognizable work problem. Explain the purpose and consequence, connect the new task to existing knowledge, demonstrate the actual procedure, let the learner practice under supervision, and give specific feedback. Use scenario-based problems and realistic specimens to assess decision-making.^{1111 Knowles MS, et al. The Adult Learner. 2025.}

CMS revised its CLIA competency brochure in May 2025. For every test performed by personnel in moderate- or high-complexity testing, competency includes six procedures:^{1010 Centers for Medicare & Medicaid Services. Assessing Personnel Competency. 2025.}

1. Direct observation of routine test performance, including patient preparation and specimen handling, processing, and testing when applicable.
2. Monitoring the recording and reporting of results.
3. Review of intermediate results or worksheets, quality-control records, proficiency-testing results, and preventive-maintenance records.
4. Direct observation of instrument performance, maintenance, and function checks.
5. Assessment with previously analyzed specimens, internal blind samples, or external proficiency-testing samples.
6. Assessment of problem-solving skills.

All six are documented at least semiannually during the first year the person tests patient specimens in the laboratory and at least annually afterward. Competency assessment is a separate step from initial training. A new analyzer or methodology requires training and demonstrated competency before patient results are reported. Proficiency testing can contribute to one procedure and cannot satisfy the complete assessment. Provider-performed microscopy uses five procedures because the instrument-performance procedure does not apply. CLIA does not require testing-personnel competency assessment in a waived-only laboratory, although training and correct performance under the manufacturer's instructions remain required.^{1010 Centers for Medicare & Medicaid Services. Assessing Personnel Competency. 2025.}

A strong assessment uses routine evidence where possible: observe a real run, review actual records, challenge a known problem, and document the assessor, date, test system, all required procedures, findings, remediation, and final determination. A checklist signed without observed evidence does not demonstrate competency.